Sonire Therapeutics Receives $13 Million in Non-Dilutive Funding from NEDO to Advance Pancreatic Cancer Treatment
Sonire Therapeutics has been awarded approximately $13 million through Japan's New Energy and Industrial Technology Development Organization (NEDO) Deep-Tech Startups Support Program. The non-dilutive funding will support the commercialization, development, and expansion of Sonire’s High-Intensity Focused Ultrasound therapy platform for pancreatic cancer treatment in both Japan and the U.S.
Topics: commercialization hifu_therapy medical_device non-dilutive_funding